Citigroup Inc. set a $3.00 price objective on NantKwest, Inc. (NASDAQ:NK) in a report released on Monday morning. The brokerage currently has a sell rating on the biotechnology company’s stock.

A number of other research firms have also issued reports on NK. BidaskClub lowered NantKwest from a hold rating to a sell rating in a report on Tuesday, August 8th. ValuEngine raised NantKwest from a strong sell rating to a sell rating in a report on Wednesday, June 14th. Zacks Investment Research raised NantKwest from a hold rating to a buy rating and set a $4.50 price objective on the stock in a report on Tuesday, May 16th. Finally, Jefferies Group LLC set a $4.00 price objective on NantKwest and gave the company a hold rating in a report on Monday, May 8th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. NantKwest currently has an average rating of Hold and a consensus price target of $8.35.

NantKwest (NK) opened at 5.55 on Monday. The stock has a 50 day moving average price of $6.61 and a 200 day moving average price of $4.89. NantKwest has a one year low of $2.71 and a one year high of $9.60. The firm’s market cap is $440.89 million.

COPYRIGHT VIOLATION NOTICE: “NantKwest, Inc. (NK) PT Set at $3.00 by Citigroup Inc.” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://theolympiareport.com/2017/08/18/nantkwest-inc-nk-pt-set-at-3-00-by-citigroup-inc.html.

In other NantKwest news, Director Steve Gorlin sold 40,000 shares of NantKwest stock in a transaction that occurred on Tuesday, June 20th. The stock was sold at an average price of $7.78, for a total value of $311,200.00. Following the sale, the director now owns 409,725 shares of the company’s stock, valued at approximately $3,187,660.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 70.19% of the stock is currently owned by insiders.

Large investors have recently bought and sold shares of the stock. Renaissance Technologies LLC bought a new stake in NantKwest during the fourth quarter worth about $140,000. Teachers Advisors LLC increased its stake in NantKwest by 53.6% in the fourth quarter. Teachers Advisors LLC now owns 40,507 shares of the biotechnology company’s stock worth $232,000 after buying an additional 14,131 shares during the last quarter. Vident Investment Advisory LLC increased its stake in NantKwest by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 138,691 shares of the biotechnology company’s stock worth $492,000 after buying an additional 23,112 shares during the last quarter. Dynamic Technology Lab Private Ltd increased its stake in NantKwest by 53.4% in the first quarter. Dynamic Technology Lab Private Ltd now owns 32,939 shares of the biotechnology company’s stock worth $117,000 after buying an additional 11,465 shares during the last quarter. Finally, Alliancebernstein L.P. increased its stake in NantKwest by 8.7% in the first quarter. Alliancebernstein L.P. now owns 33,800 shares of the biotechnology company’s stock worth $120,000 after buying an additional 2,700 shares during the last quarter. Institutional investors own 20.73% of the company’s stock.

About NantKwest

Receive News & Ratings for NantKwest Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.